Management

Chief Executive Officer

Paul Goldenheim, MD

Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies including Neurophage, Hydra Biosciences, Acesion and RSPR. He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Paul also serves on the board of directors of The Big Apple Circus. Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He received his A.B. from Harvard College magna cum laude with highest honors in biochemical sciences and his M.D. from Harvard Medical School..

 

 

Chief Medical Officer

Edward Fang, MD

Edward Fang is a physician with 10 years of antibiotic drug development experience. Prior to joining Adenium, Dr. Fang was Director of Clinical Sciences at Trius Therapeutics where he was the clinical lead on pivotal phase 3 skin infection studies, as well as phase 1 and 2 trials, and contributed to the NDA leading to the approval of Sivextro (tedizolid) by the FDA (Jun 2014). Previously, Dr. Fang was Associate Director of Clinical Sciences at Cerexa, where he was the clinical lead on phase 1 and 2 studies, and contributed to the NDA leading to the approval of Teflaro (ceftaroline) by the FDA (Oct 2010). Earlier, Dr. Fang was Editor-in-Chief at Epocrates, developing content and products for software used by physicians and other healthcare professionals. Dr. Fang earned a BA from Stanford University, and an MD from the University of California at Los Angeles, where he also completed a residency in internal medicine.

 

 

Project Director

Magnus Strandh, PhD

Dr. Strandh is a project director and senior scientist with more than 15 years of biopharmaceutical drug discovery and development experience. Prior to joining Adenium in 2016, Dr. Strandh held a position at Symphogen as a senior scientist and project manager for many therapeutic antibody discovery projects within oncology and infectious diseases, including collaborations with e.g. Genentech. Previously, Dr. Strandh was scientist at Trellis Bioscience, which he joined when the company started. He was instrumental in the development of their proprietary antibody screening platform and their discovery projects within infectious diseases, osteoporosis and oncology. Magnus Strandh received his PhD in Immunotechnology from Lund University, Sweden, in 2010.

 

 

CMC/project management

Kim Hejnæs, M.Sc.

Kim Hejnæs is professor in biotechnology at University of Aalborg, Denmark and co-founder of  SMC Biotech, help4biotech, invest4biotech and Hejnæs Consult AB.  He has for the last 15 years been specializing in project management of drug development programs and served as a project director at CMC Biologics for several years. Professor Hejnæs has a strong background in protein chemistry, and he served for many years as a principal scientist in research and development at Novo Nordisk, Denmark. Kim Hejnæs holds a M. Sc. in Biochemistry from University of Copenhagen.

 

 

Regulatory affairs/project management

 Dorrit Andersen, M.Sc.

Dorrit Andersen has more than 30 years of experience in the biopharmaceutical industry working with global development of pharmaceuticals (quality, clinical and regulatory). Dorrit has previously worked as global regulatory affairs director at Novo Nordisk and before establishing her consultancy business as regulatory affairs manager at Symphogen and Genmab. Prior to Novo Nordisk she was head of regulatory affairs and clinical project manager at Ciba-Geigy DK. Her latest accomplishment as a consultant is the submission and approval of a recombinant protein therapeutic in the USA and EU. Dorrit Andersen holds a degree in pharmacy from the University of Copenhagen.

 

 

 

 

 


Adenium Biotech ApS | Ole Maaloesvej 3 | 2200 Copenhagen N | Denmark | CVR 33882785